Table 1 |
||
|
Cohort characteristicsa |
||
|
Cohort |
Patients (n = 214) |
Controls (n = 31) |
|
|
||
|
MBL genotype group A, n (%) |
114 (53.3) |
16 (51.6) |
|
MBL genotype group B, n (%) |
59 (27.6) |
8 (25.8) |
|
MBL genotype group C, n (%) |
41 (19.2) |
7 (22.6) |
|
Number of Caucasians, n (%) |
207 (96.7) |
31 (100) |
|
Number of nulliparous women, n (%) |
113/214 (52.8) |
14/31 (45.2) |
|
Mean age at delivery, yr (± SD) (range) |
32.5 ± 3.7 (21.9 to 40.6) |
32.1 ± 4.5 (24.2 to 40.1) |
|
Mean gestational age at delivery, wk (range) |
39.4 (31.4 to 42.1) |
40.0 (34.7 to 42.0) |
|
Smoking during pregnancy, n (%) |
6/206 (2.9) |
3/31 (9.7) |
|
Miscarriage, n (%) |
23 (10.7) |
- |
|
Hypertension, n (%) |
25/210 (11.7%) |
2 (6.5) |
|
Preeclampsia, n (%) |
4/210 (1.9) |
1 (3.2) |
|
Anti-CCP-positive, n (%) |
134/213 (62.9) |
- |
|
Rheumatoid factor (IgM)-positive, n (%) |
161/214 (75.1) |
- |
|
Erosive disease, n (%) |
136/210 (64.8) |
|
|
Median disease duration at delivery, yr (range) |
7.9 (0.7 to 29.0) |
- |
|
Use of prednisone in first trimester, n (%) |
60/164 (36.6%) |
|
|
Median number of DMARDs (including prednisone) prior to conceive (min-max) |
2.3 (0-6) |
- |
|
Use of methotrexate prior to conception, n (%) |
120/212 (56.6) |
- |
|
DAS28-CRP3 >3.2 in first trimester, n (%) |
84/155 (54.2) |
- |
|
Classification of disease activity during pregnancy |
||
|
Good response or moderate response, n (%) |
40/84 (47.6) |
- |
|
No response, n (%) |
44/84 (52.4) |
- |
|
Classification of disease activity during postpartum period (early flare) |
||
|
Severe or moderate deterioration, n (%) |
39/167b (23.4) |
- |
|
No deterioration, n (%) |
128/167b (76.6) |
- |
|
Classification of disease activity during postpartum period (late flare) |
||
|
Severe or moderate deterioration, n (%) |
28/152b (10.3) |
- |
|
No deterioration, n (%) |
124/152b (45.6) |
- |
|
|
||
|
aMBL, mannose-binding lectin; n, number; SD, standard deviation; anti-CCP, anti-cyclic citrullinated peptide; IgM, immunoglobulin M; DMARDs, disease-modifying antirheumatic drugs; DAS28-CRP3, Disease Activity Score 28 using three variables, including C-reactive protein; bcases are missing because DAS score data are missing in a proportion of patients. |
||
|
van de Geijn et al. Arthritis Research & Therapy 2011 13:R10 doi:10.1186/ar3231 |
||
